OSOBENNOSTI TEChENIYa VIRUSNYKh GEPATITOV U PATsIENTOV S ONKOGEMATOLOGIChESKIMI ZABOLEVANIYaMI


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Frequent complication of chemotherapy in patients with hematologic malignancies is a abnormal liver function. The main causes of dysfunction, as a rule, are viruses hepatitis B and C, cytomegalovirus, and herpes simplex virus. HBV and HCV have been reported to cause severe liver dysfunction, including fulminant hepatitis, reactivation or increase viral replication. Viral hepatitis and their complications have a negative impact on the course of the main disease in cancer patients, reduce the effectiveness of anticancer therapy, worsen prognosis, quality of life and survival of patients and pose a health risk to patients who have recovered from blood cancers because of the risk of formation of liver cirrhosis and hepatocellular carcinoma. Early diagnosis and treatment of viral hepatitis are essential to minimize mortality from this diseases

全文:

受限制的访问

参考

  1. Nordbo S.A., Skaug K, Holter E., Waage A., Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 2000;65:86-7.
  2. Steinberg J.L., Yeo W., Zhong S., et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000;60:249-55.
  3. Xunrong L., Yan A.W., Liang R., Lau G.K. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 2001;11:287-99.
  4. Yeo W., Chan P.K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
  5. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
  6. Zekri A.R., Mohamed W.S., Samra M.A., et al. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004;13:305-11.
  7. Knoll A., Boehm S., Hahn J., Holler E., Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:925-29.
  8. Kumagai K., Takagi T., Nakamura S., et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl 1):107-9.
  9. Lee W.M. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45. Lavanchi D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Virol Hepat 2004;11:97-107.
  10. Yim H.J., Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81.
  11. Blackberg J., Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-97.
  12. Firpi R.J., Martin P. Update on hepatitis B treatment. Med Gen Med 2002;4:9.
  13. de Franchis R., Hadengue A., Lau G., et al. EASL International Consensus Conference on Hepatitis B. 13-4 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3-25.
  14. Kitano K., Kobayashi H., Hanamura M., et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006;77:255-58.
  15. Lubel J.S., Testro A.G., Angus P.W. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007;37:705-12.
  16. Hui C.K., Cheung W.W., Zhang H.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131:59-68.
  17. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 2007;136:699-712.
  18. Lok A.S., Liang R.H., Chiu E.K., et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100:182-88.
  19. Zhong S., Yeo W., Schroder S, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004;11:55-9.
  20. Hui C.K., Lie A., Au W.Y. et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005;106:464-69.
  21. Maguire C.M., Crawford D.H., Hourigan L.F., et al. Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. J Gastroenterol Hepatol 1999;14:801-3.
  22. Markovic S., Drozina G., Vovk M., Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925-30.
  23. Silvestri F., Sperotto A., Ermacora A., et al. Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. Haematologica 2000;85:327-29.
  24. Ustun C., Koc H., Karayalcin S., et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;20:289-96.
  25. Wong G.C., Tan P., Goh Y.T., et al. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 1996;25:500-03.
  26. Yagci M., Sucak G.T., Haznedar R. Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia. Am J Hematol 2000;64:233-34.
  27. Yeo W., Steinberg J.L., Tam J.S., et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999;59:263-69.
  28. Lau G.K., He M.L., Fong D.Y., et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-09.
  29. Martyak L.A., Taqavi E., Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28(1):28-38.
  30. Yeo W., Chan P.K., Ho W.M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-34.
  31. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007;45:507-39.
  32. Leung N.W., Tam J.S., Lau G.T., et al. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994;73:1143-48.
  33. Onozawa M., Hashino S., Izumiyama K., et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplanta -tion in patients with previous hepatitis B virus infection. Transplantation 2005;79:616-19.
  34. Senecal D., Pichon E., Dubois F., et al. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 1999;24:1243-44.
  35. Dreger P., Rautenberg P., Kneba M., Schmitz N. Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC. Bone Marrow Transplant 2000;26:114-16.
  36. Iwai K., Tashima M., Itoh M., et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000; 25:105-8.
  37. Dhedin N., Douvin C., Kuentz M., et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616-19.
  38. Sekine R., Taketazu F., Kuroki M., et al. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy. Int J Hematol 2000;71:256-58.
  39. McIvor C., Morton J., Bryant A., et al. Fatal reactivation of precore mutant hepatitis B virus associ ated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med 1994; 121:274-75.
  40. Dai M.S., Wu P.F., Shyu R.Y., Lu J.J., Chao T.Y. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-46.
  41. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005;55:828-31.
  42. Jang J.W., Choi J.Y., Bae S.H., et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-40.
  43. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742-49.
  44. Li Y.H., He Y.F., Jiang W.Q., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106:1320-25.
  45. Yeo W., Ho W.M., Hui P., et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:209-15.
  46. Saab S., Dong M.H., Joseph T.A., Tong M.J. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007;46:1049-56.
  47. Hsiao L.T., Chiou T.J., Liu J.H., et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12:84-94.
  48. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
  49. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125: 1714-22.
  50. Perez-Roldan F., Gonzalez-Carro P., Villafanez-Garcia M.C. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 2005;352:310-11.
  51. Cortelezzi A., Vigano M., Zilioli V.R., et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006;35:467-69.
  52. Fouillard L., Serfaty L., Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37:625-26.
  53. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209.
  54. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.
  55. Davis G.L. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004;4:7-17.
  56. Locasciulli A., Testa M., Valsecchi M.G., et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999;68:1486-91.
  57. Peffault de Latour R., Levy V., Asselah T., et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103:1618-24.
  58. Ivantes C.A., Amarante H., Ioshii S.O., Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 2004;33:1181-85.
  59. Strasser S., Myerson D., Spurgeon C.L., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999;29:1893-99.
  60. Strasser S.I., Sullivan K.M., Myerson D., et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999;93:3259-66.
  61. Zuckerman E., Zuckerman T., Douer D., Qian D., Levine A.M. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998;83:1224-30.
  62. Ribas A., Gale R.P. Should people with hepatitis C virus infection receive a bone marrow transplant? Bone Marrow Transplant 1997;19:97-9.
  63. Frickhofen N., Wiesneth M., Jainta C., et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994;83:1998-2004.
  64. Gigliotti A.R., Fioredda F., Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003;25:184-92.
  65. Ho V.T., Revta C., Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008 Feb;41:229-37.
  66. Peffault de Latour R., Levy V., Asselah T., et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005;36:709-13.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##